Panitumumab. en las nuevas guías de CCRm - page 9

0
20
40
60
80
100
90
70
50
30
10
PRIME study RAS analysis
OS (primary analysis)
• Douillard JY, et al. N Engl J Med 2013; 369:1023-34, supplements at:
http://www.nejm.org/doi/suppl/10.1056/NEJMoa1305275/suppl_file/nejmoa1305275_appendix.pdf
• MT RAS, MT in any KRAS or NRAS exon 2, 3, or 4
• (excludes 7 patients harbouring KRAS/NRAS codon 59 mutations)
0
20
40
60
80
100
90
70
50
30
10
WT KRAS exon 2 / MT other RAS
HR = 1.29 (95% CI, 0.79–2.10)
P = 0.305
HR = 1.25 (95% CI, 1.02–1.55)
P = 0.034
Events
n (%)
Median (95% CI)
months
Panitumumab +
FOLFOX4 (n = 51)
35 (69) 17.1 (10.8–19.4)
FOLFOX4 (n = 57) 33 (58) 18.3 (13.0–23.2)
Events
n (%)
Median (95% CI)
months
Panitumumab +
FOLFOX4 (n = 272)
187 (69) 15.6 (13.4–17.9)
FOLFOX4 (n = 276) 175 (63) 19.2 (16.7–21.8)
Proportion alive (%) Proportion alive (%)
Months Months
0 36 4 8 12 16 28 32 20 24 0 36 4 8 12 16 20 24 28 32
MT RAS